Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 30, 2026

MaxLinear (MXL) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
MaxLinear (MXL) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Thursday, January 29, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • MaxLinear is gaining share in PON vs competition and regaining previously lost share in cable

    80% confidence
  • Customer engagement for Rushmore is accelerating faster than expected

    80% confidence
  • CPO is in early innings and the future will be more varietal than just pure CPOs

    80% confidence
  • Infrastructure will become the largest revenue contributor in 2026

    80% confidence
  • Connectivity expected to grow in 2026 driven by Wi-Fi 7 and 2.5GbE Ethernet

    80% confidence
  • Keystone PAM4 DSP expected to generate $100M-$130M revenue in 2026 with 4M-6M transceiver unit volume

    80% confidence
  • OpEx expected to grow 4%-5%, typically targeting half of revenue growth rate

    80% confidence
  • Gross margin target is to exit the year starting with 6% vs current 5%

    80% confidence
  • Lead times for optical products are 28 weeks

    80% confidence
  • MaxLinear is among the top 3 deployers of PAM4 DSP globally

    80% confidence
  • 80%+ of business is not exposed to supply chain tightness

    80% confidence
  • Infrastructure will grow faster in 2026 than in 2025

    80% confidence
  • Broadband revenue expected to be down year-over-year in 2026 due to seasonally soft H1 and DOCSIS 4.0 transition

    80% confidence
  • The pluggable market as a whole is still growing very fast

    80% confidence
  • Panther storage accelerator revenue expected to at least double in 2026 vs 2025, with potential to double again in 2027

    80% confidence
  • LRO has some traction but will be a fraction of the market

    80% confidence
  • MaxLinear strengthened its relative position in certain geographies for 800G and is #3 in the US

    80% confidence
  • LPO is very niche and will be a very small fraction of the market, limited to controlled environments and less relevant for 1.6 terabits

    80% confidence
  • MaxLinear does not compete on price; wins are based on performance and pricing is the last decision factor

    80% confidence
  • Company expects to outgrow the industry in 2026

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com